Levrom-M Syrup is a combination medication containing Levocetirizine 2.5 mg and Montelukast 4 mg, formulated for the management of allergic conditions. Levocetirizine is a potent, second-generation antihistamine that selectively inhibits peripheral H1 receptors, effectively reducing symptoms such as sneezing, nasal congestion, rhinorrhea, and pruritus associated with allergic rhinitis and chronic urticaria. Montelukast is a leukotriene receptor antagonist that blocks the action of cysteinyl leukotrienes, thereby decreasing inflammation, bronchoconstriction, and mucus production in the airways. The synergistic action of these two agents provides comprehensive relief from allergic manifestations, including seasonal and perennial allergic rhinitis, as well as mild to moderate asthma. Levrom-M Syrup is particularly beneficial in pediatric patients due to its palatable formulation and appropriate dosing. It is generally well tolerated, with minimal sedative effects compared to first-generation antihistamines. The medication should be used under medical supervision, with caution advised in patients with hepatic impairment or a history of neuropsychiatric events. Levrom-M Syrup offers an effective therapeutic option for controlling allergic symptoms and improving quality of life in affected individuals.